healthcare

Teva pharma receives a booster shot with FDA's approval for its generic version of EpiPen and EpiPen Jr. This will be a real threat to Mylan. Also, Teva and Regeneron announce positive Phase 3 Fasinumab results in patients with chronic pain from osteoarthritis...

Health insurer Humana (HUM) today reported its second-quarter earnings that surpassed analysts’ forecast, mainly due to surge in enrollment in the company’s Medicare Advantage plans. https://news.alphastreet.com/humana-earnings-q2-2018/

Healthcare giant Johnson & Johnson (JNJ) reported a beat on both the top and bottom line expectations as it posted its Q2 2018 earnings. This was aided by a double-digit growth in Pharmaceutical business and the accelerating sales momentum in the Medical Devices business...

In the past two weeks, Celgene has reported positive results from 3 clinical trials. This includes two studies with its partner Acceleron. https://news.alphastreet.com/celgene-gets-a-booster-shot-from-recent-positive-clinical-trial-results/

Trump has been speaking and tweeting about the higher drug prices for nearly two years and still he has not taken any steps in reducing the prices of the drugs. Pfizer and other pharma companies are taking advantage and increasing their drug prices often. When will this stop...

On Monday, WSJ reported that Stryker is in talks with Boston Scientific for a potential acquisition. But today, Stryker confirmed that it didn't have any discussion with Boston Scientific. https://news.alphastreet.com/stryker-confirms-that-it-didnt-bid-for-boston-scientific/

https://www.linkedin.com/pulse/hospitality-hospitals-service-excellence-patient-eric-rubino/

Pfizer (PFE) is an interesting stock to follow. Apart from being a great dividend stock, the company also boasts of a diversified portfolio, strong free cash flow, and consistency in beating earnings expectations. Let’s quickly take a look at the pros and cons...

Merck reported a 6% increase in worldwide sales to $10 billion for the first quarter of 2018 compared to the prior year period. Pharmaceutical sales grew 9% to $8.9 billion driven primarily by growth in oncology, hospital acute care and diabetes. This was partially offset by lower sales in...

Alexion reported a rise in Q1 2018 earnings and revenue, and lifted the guidance for the year. Along with this, the company also reported a positive top line results for its Phase 3 study. The company that specializes in manufacturing drugs for rare disorder reported a 7% increase in its revenue...

AbbVie’s first quarter results topped analyst consensus both on earnings and sales front, driven by double-digit sales growth from Humira, Imbruvica, and HCV. Sales improved 21.4% to $7.9 billion, while adjusted earnings came in at $1.87, up 46%. The company also has decided to buyback shares to...

Amgen reported an increase in first quarter earnings, driven by broad-based growth in product sales. Both earnings and sales topped street estimates. Earnings rose 16% year-over-year to $3.25 per share during the quarter. Besides higher product sales, the growth was also driven by a decline in...

Biogen, whose shares fell nearly 16.5% this year, saw it further dip 2.4% to $259.30 in pre-market trade, despite the strong first-quarter earnings. Earnings, excluding items, jumped to $6.05 per share this quarter from last year’s $5.20 per share. On a diluted basis, Biogen reported earnings of...

Abbott reported worldwide sales of $7.4 billion for the first quarter of 2018, an increase of 16.7% versus the prior-year period, helped by new product launches. Net earnings on a GAAP basis came in at $418 million or $0.23 per share, down slightly from the prior-year quarter. On an adjusted...

Intuitive Surgical reported a first-quarter profit that exceeded market consensus. The company’s flagship da Vinci surgical system continues to be a revenue driver for the instruments and accessories segment. With total revenue jumping 25% to about $858 million, the instruments maker saw its...

Sanofi plans to offload its European generics business Zentiva that it acquired in 2009. Several bidders had earlier dropped out of an auction, but latest news suggests that the company is nearing an agreement and may soon finalize the sale. According to Reuters, private equity firm Advent...

JNJ reported a 12.6% increase in sales to $20 billion for the first quarter of 2018 as domestic sales grew 6.1% and those from international markets improved about 20%. Net earnings fell slightly to $4.4 billion or $1.60 per share compared to the prior-year period. After adjusting for certain...

Both Pfizer and Merck planned to dispose their consumer health businesses since they failed to return profits, dampening their efforts to innovate in other segments. However, bidders eventually lost interest in Merck’s consumer health line, even as the auction of Pfizer’s consumer health unit...

Sale of its blockbuster arthritis drug, Remicade, was particularly impacted by the rising influence of biosimilars, especially in the international markets. It needs to be seen how much the company has resisted this trend in the first quarter...

Merck is hell-bent on becoming a major player in the lucrative immune-oncology space as its blockbuster cancer drug Keytruda met its goal of extending the lifespan of cancer patients. https://news.alphastreet.com/merck-sets-the-bar-high-for-rivals-with-positive-keytruda-trial-results/